Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Double-blind, Dose-ranging, Multi-centered Trial to Evaluate the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia

NCT01455844 is registered in ClinicalTrials.gov with Grace Therapeutics Inc. as lead sponsor.

NCT NCT01455844
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01455844 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Double-blind, Dose-ranging, Multi-centered Trial to Evaluate the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high Hypertriglyceridemia
Lead sponsor
Grace Therapeutics Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2011
Completion date
August 31, 2014
Enrollment
387 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

hypertriglyceridemia